Zacks
0
All posts from Zacks
Zacks in Our Research. Your Success.,

Cooper Companies' Genesis Buyout to Check Competition

A division of The Cooper Companies Inc. COO, CooperSurgical (CSI), recently acquired Plymouth, MI-based Genesis Genetics for approximately $60 million. The company specializes in pre-implantation genetic screening (PGS) and pre-implantation genetic diagnosis (PGD) tests, which are used during the in-vitro fertilization (IVF) process.

PGS is a comprehensive chromosome screening that examines embryos for chromosomal abnormalities, which is the most common reason for a miscarriage. With the help of the test, the number of embryos with an incorrect number of chromosomes can be minimized before transfer to the womb.

Moreover, the test helps in understanding the chromosome abnormalities that result in fewer embryos transferred,and subsequently fewer miscarriages. Further, by having the chromosome status of each embryo, the test helps in increasing the likelihood of conceiving with IVF.

The PGD test helps in detecting genetic diseases in embryos during the IVF procedure. The test also helps in lowering the risks embryos may suffer from inherited genetic disorders.

Notably, CooperSurgical expanded its presence in the fertility market with the acquisition of Reprogenetics, a genetics laboratory specializing in PGS and PGD. The takeover opened up markets in the U.S., Spain, the UK, Japan, Peru, South America and the UAE for the company’s products.

Meanwhile, the Genesis acquisition significantly reduces competition for Reprogenetics. Moreover, Genesis boasts a strong clientele and presence in countries like Brazil, England, South Africa, Jordan and Taiwan, apart from the U.S. Thus, the buyout will help Cooper Companies fortify its hold in these regions.

Cooper Companies believes that CSI’s long-term growth will be driven by the fertility segment, which reported revenues of $31 million, up 24% from the year-ago quarter. The addition of Genesis will drive top-line growth. As of Mar 31, 2016, Genesis reported trailing twelve-month revenues of approximately $24 million. The revenue growth is forecasted to be in the low double digits over the coming years, which is a significant positive in our view.

Meanwhile, the acquisition is neutral to Cooper Companies’ earnings in fiscal 2016 and is expected to be accretive thereafter. Management forecasts CSI revenues at around $355–$365 million, compared with the previous $325–$335 million range for fiscal 2016.

We believe accretive acquisitions will boost Cooper Companies’ competitive position in the women healthcare space against the likes of Johnson & Johnson's JNJ Ethicon Endo-Surgery, Boston Scientific BSX, Olympus and Covidien. The Genesis acquisition also lends Cooper Companies a competitive edge over Good Start Genetics and Igenomix.

Zacks Rank & A Key Pick

Currently, Cooper Companies carries a Zacks Rank #2 (Buy). Another favorably ranked stock in the medical sector is Abiomed ABMD, which sports a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. http://www.zacks.com/registration/pfp/?ALERT=RPT_7BST_LP194&... blog">Click to get this free report >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
JOHNSON & JOHNS (JNJ): Free Stock Analysis Report
 
ABIOMED INC (ABMD): Free Stock Analysis Report
 
BOSTON SCIENTIF (BSX): Free Stock Analysis Report
 
COOPER COS (COO): Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research